INS and fatty liver disease: In contrast, GLP‐1RAs are believed to exert hepatoprotective effects through multiple mechanisms, including: (1) reduction in hepatic steatosis through improved insulin sensitivity and decreased de novo lipogenesis; (2) anti‐inflammatory effects mediated by suppression of NF‐κB and reduction in oxidative stress; (3) modulation of the gut‐liver axis through changes in microbiome composition and intestinal permeability; and (4) indirect benefits from weight loss and improved glycemic control.